Literature DB >> 30286636

Excision with primary midline closure compared with Limberg flap in the treatment of sacrococcygeal pilonidal disease: a randomised clinical trial.

M Arnous1, H Elgendy1, W Thabet2, S H Emile2, S A Elbaz1, W Khafagy2.   

Abstract

BACKGROUND: Although several surgical techniques for treatment of sacrococcygeal pilonidal sinus (SPND) have been described, there is no consensus on the optimal surgical procedure. In this study we compared excision with primary closure and Limberg flap in the treatment of SPND.
METHODS: This was a prospective randomised clinical trial in patients with SPND who were randomly allocated to one of two groups: group I (excision and primary closure) and group II (Limberg flap technique). The primary outcome of the trial was recurrence of SPND whereas postoperative complications, return to work and cosmetic results were the secondary outcomes.
RESULTS: Sixty patients were included, with a mean age of 24.1 years and mean body mass index (BMI) of 26.8 kg/m2. Group 1 had significantly shorter operation time than group II. Both groups had similar hospital stay and comparable complication rates (43.3% vs 30%; P = 0.4). Group I had significantly higher recurrence rate (20% vs 0; P < 0.02) and significantly better cosmetic satisfaction score than group II. Being hairy (P = 0.04), positive family history (P = 0.03), diabetes mellitus (P = 0.005) and history of previous surgery for SPND (P = 0.01) were the significant predictors for recurrence.
CONCLUSIONS: The Limberg flap is an effective technique for the treatment of SPND with very low recurrence rate and comparable complication rate and hospital stay to excision and primary closure. Excision and primary closure offered the advantages of quicker healing time, earlier resumption of daily activities, better cosmetic results, which may render it more suitable for patients with low risk for recurrence.

Entities:  

Keywords:  Limberg flap; Midline; Pilonidal sinus; Postoperative complication; recurrence

Mesh:

Year:  2018        PMID: 30286636      PMCID: PMC6303836          DOI: 10.1308/rcsann.2018.0144

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  6 in total

1.  D-shape asymmetric excision in recurrent pilonidalis disease: an analytic longitudinal long-term evaluation.

Authors:  Luigi Brusciano; Gianmattia Del Genio; Salvatore Tolone; Michele Schiano di Visconte; Giorgia Gualtieri; Gianmattia Terracciano; Claudio Gambardella; Ludovico Docimo
Journal:  Updates Surg       Date:  2019-03-18

Review 2.  Karydakis procedure versus Limberg flap for treatment of pilonidal sinus: an updated meta-analysis of randomized controlled trials.

Authors:  Sameh Hany Emile; Sualeh Muslim Khan; Samer Hani Barsom; Steven D Wexner
Journal:  Int J Colorectal Dis       Date:  2021-04-10       Impact factor: 2.571

3.  Pilonidal sinus disease recurrence at a tertiary care center in Riyadh.

Authors:  Ibrahim Tawfiq Albabtain; Abdullah Alkhaldi; Lama Aldosari; Lina Alsaadon
Journal:  Ann Saudi Med       Date:  2021-06-01       Impact factor: 1.526

4.  Pilonidal Cyst Excision: Primary Midline Closure with versus without Closed Incision Negative Pressure Therapy.

Authors:  Silvio Gabor; Murillo de Lima Favaro; Ruy Francisco Pimentel Pedroso; Bárbara Henriqueta Ferreira Duarte; Rafaela Novo; Ana Paula Iamarino; Marcelo Augusto Fontenelle Ribeiro
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-03-23

5.  Comparative analysis on the effect of Z-plasty versus conventional simple excision for the treatment of sacrococcygeal pilonidal sinus: A retrospective randomised clinical study.

Authors:  Yong-Ping Yang; Ling-Yun Yu; Yi-Zhuo Wang; Jian Shi; Jian-Nan Li; Feng-Jia Shang; Jiao Wu; Tong-Jun Liu
Journal:  Int Wound J       Date:  2020-01-23       Impact factor: 3.315

6.  Surgical procedures in the pilonidal sinus disease: a systematic review and network meta-analysis.

Authors:  Siwei Bi; Kaibo Sun; Shanshan Chen; Jun Gu
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.